Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Burns
Interventions: Vitamin K; Drug
Lead sponsor: Joseph M. Still Research Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Peritoneal Carcinomatosis
Interventions: Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC); Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatic Impairment
Interventions: AG-120 (Ivosidenib); Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: HIGH GRADE GLIOMA
Interventions: TH-302 preoperative, Placebo, TH-302 (escalating) with bevacizumab 10mg/kg; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rectal Cancer
Interventions: Ultrafractionated radiotherapy for rectal cancer; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anterior Tibial Compartment Syndrome
Interventions: Not listed
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 3
States / cities: Athens, Georgia • Atlanta, Georgia

Conditions: Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
Interventions: 18F-NaF, 18F-DCFPyL, 18F-FDG; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Beta-Thalassemia
Interventions: ACE-536; Drug
Lead sponsor: Celgene; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Antibodies Involved in Healthy Aging
Interventions: Not listed
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 90 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Interventions: NC525; Drug
Lead sponsor: NextCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Duarte, California • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule; Drug · Other
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Kidney Transplantation, Glomerular Filtration Rate
Interventions: No intervention; Other
Lead sponsor: Paris Translational Research Center for Organ Transplantation; Other
Eligibility: 18 Years and older
Enrollment: 11,412 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19, Burnout, Burnout, Professional, Work-related Illness, Work-Related Stress, SARS-CoV-2 Infection
Interventions: Positive Affect Regulation sKills (PARK); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions: BYDUREON, Placebo; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Risk Perceptions, Decision Making, Alcohol
Interventions: Health warning statement evaluations (bottles), Health warning statement evaluations (ads); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Fountain Valley, California • San Diego, California • Vista, California + 11 more

Conditions: Macular Degeneration
Interventions: VEGF Trap; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Intensity-Modulated Radiation Therapy, Peposertib; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Malignant Neoplasmas, Solid Tumors
Interventions: gemcitabine, ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Denver, Colorado • Buffalo, New York

Conditions: KRAS Altered Advanced or Metastatic Solid Tumors
Interventions: AMG 410, Pembrolizumab, Panitumumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
Interventions: Acupuncture; Procedure
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Gainesville, Florida + 5 more

Search by objective public record fields.

Comparison of Vitamin K Doses in Patients With Larger Burn Injuries

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

Ultra-fractionated Radiotherapy for Rectal Cancer

The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

Estimating Glomerular Filtration Rate in Kidney Transplant Recipients

Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Designing Effective Alcohol Health Warnings: An Experimental Study With Adults in the U.S.

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Acupuncture for Sexual Dysfunction

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures